Leerink Partnrs Comments on RYTM Q2 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Rhythm Pharmaceuticals in a report released on Monday, July 7th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($0.87) for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals' Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.49) EPS, FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($2.07) EPS, FY2028 earnings at ($0.42) EPS and FY2029 earnings at $1.28 EPS.

A number of other research firms have also recently weighed in on RYTM. JMP Securities reaffirmed a "market outperform" rating and set a $84.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Thursday, June 26th. The Goldman Sachs Group began coverage on Rhythm Pharmaceuticals in a research note on Thursday. They set a "buy" rating and a $97.00 target price on the stock. Stifel Nicolaus lifted their target price on Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Oppenheimer lifted their target price on Rhythm Pharmaceuticals from $76.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday. Finally, Needham & Company LLC reissued a "buy" rating and set a $95.00 target price (up previously from $72.00) on shares of Rhythm Pharmaceuticals in a research note on Wednesday. Fourteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $91.00.

Rhythm Pharmaceuticals Price Performance

Shares of RYTM stock traded down $1.76 during trading hours on Thursday, reaching $87.28. 577,279 shares of the company traded hands, compared to its average volume of 586,640. Rhythm Pharmaceuticals has a 12-month low of $40.61 and a 12-month high of $94.80. The company has a market cap of $5.55 billion, a P/E ratio of -30.99 and a beta of 2.26. The firm has a 50-day moving average price of $63.88 and a 200 day moving average price of $59.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. The firm had revenue of $37.72 million during the quarter, compared to analysts' expectations of $40.43 million. During the same period in the previous year, the business posted ($2.35) earnings per share. The company's revenue for the quarter was up 25.9% on a year-over-year basis.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in RYTM. Westfield Capital Management Co. LP bought a new position in shares of Rhythm Pharmaceuticals in the 1st quarter worth $71,038,000. Janus Henderson Group PLC raised its position in shares of Rhythm Pharmaceuticals by 103.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company's stock worth $68,309,000 after acquiring an additional 621,432 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Rhythm Pharmaceuticals by 75.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,199,053 shares of the company's stock worth $63,515,000 after acquiring an additional 513,901 shares in the last quarter. Marshall Wace LLP raised its position in shares of Rhythm Pharmaceuticals by 70.4% in the 4th quarter. Marshall Wace LLP now owns 692,803 shares of the company's stock worth $38,783,000 after acquiring an additional 286,188 shares in the last quarter. Finally, Siren L.L.C. bought a new position in shares of Rhythm Pharmaceuticals in the 1st quarter worth $14,701,000.

Insiders Place Their Bets

In related news, CAO Christopher Paul German sold 2,069 shares of the business's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $67.19, for a total transaction of $139,016.11. Following the completion of the transaction, the chief accounting officer owned 1,889 shares in the company, valued at $126,921.91. The trade was a 52.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Pamela J. Cramer sold 7,031 shares of the company's stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $65.09, for a total value of $457,647.79. Following the completion of the sale, the insider owned 19,209 shares of the company's stock, valued at $1,250,313.81. This represents a 26.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,195 shares of company stock worth $1,599,572 in the last 90 days. 6.10% of the stock is owned by insiders.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.